24 SKIN CARE For each volunteer and facial area, the
number of arrows contributing to a lifting effect (arrows between 0 and 90 degrees of orientation) and the length of the arrows was quantified. The % Lifting effect was calculated considering the number of arrows multiplied by their mean length for each facial zone versus the placebo cream (Figure 8B). A cream containing 2% of the novel peptide
solution generated a lifting effect in the crow’s feet area, which can be appreciated by the greater number of upward red arrows over the skin surface on the active cream side of the face versus the placebo side (Figure 9A, lower panel). Using the computer vision approach, this
increase in lifting was quantified to be 16.3% versus placebo cream (Figure 9A, upper panel). Moreover, treatment with the active ingredient showed even better performance than the group using the microcurrent device over the same period. Similarly, in the upper cheek area, the
side of the face corresponding to the active cream treatment showed a greater number of upward red arrows compared to the placebo side, where fewer red arrows were found (Figure 9B, lower panel). With the computer vision technique, the upper cheek lifting effect was determined to be 94.6% versus placebo cream. This effect was similar to
A 0
-2 -4 -6 -8
-10 -12 -14 -16 -18
Placebo ** -13.1% ****
Microcurrent device
2% Uplevity e-Lift peptide solution
B 0
-2 -4 -6 -8
-10 -12 -14 -16
Placebo -9.6% **** ***
Microcurrent device
2% Uplevity e-Lift peptide solution
2% Uplevity
e-Lift peptide solution
Female volunteer 10, 46 years old Female volunteer 1, 50 years old 0 days 7 days 2% Uplevity
e-Lift peptide solution
Female volunteer 13, 55 years old
Figure 10: Overall upper face lifting effect, showing the initial and final time 2D images for both, active and placebo cream face sides
the group applying the microcurrent device (Figure 9B). A visible lifting effect on the upper face
treated with the active cream containing 2% of the novel peptide solution versus the initial time is clearly noticed after 28 days of product application, whereas no lifting effect was detected on the placebo side (Figure 10).
0 days 7 days
Anti-wrinkle efficacy The length of the wrinkles (µm) in the crow’s feet region and the underneath the eye was measured by means of a real 3D microtopography imaging system based on fringe projection (PRIMOS) after seven days of product treatment. Active cream containing 2% of the novel
peptide solution showed a reduction of the length of wrinkles in a statistically significant manner in both facial zones by -13.1% and -9.6%, respectively (Figures 11A and 11B, left panels). These efficacy results were very similar to the anti-wrinkle improvements found in the group using the microcurrent device. Moreover, a visual improvement of
Female volunteer 10, 46 years old
wrinkles can be visualized from the facial images (Figures 11A and 11B, right panels) after seven days of treatment with an active cream containing 2% of the novel peptide solution, as well as after the use of the microcurrent device over the same period of time.
Conclusion The novel peptide from Lubrizol Life Science emerges as an innovative topical active ingredient which confers a rejuvenated lifting and anti-wrinkle effect, inspired by microcurrents devices. In vitro, it has been demonstrated to activate the same biological functions as microcurrent stimulation: improving dermal contraction and muscle tone. Clinically, the novel peptide confers an
Female volunteer 8, 59 years old
Figure 11: A) Left panel: percentage of decrease in wrinkle length in the crow´s feet (**p<0.01, **** p<0.0001, vs. initial time, calculated using a paired Student´s t-test after checking the normality distribution by a Shapiro-Wilk test). Right panel: representative images showing the anti-wrinkle effect of a cream containing 2% Uplevity e-Lift peptide solution and after a microcurrent treatment. B) Left panel: percentage of decrease in wrinkle length in the underneath the eye region (***p<0.001, **** p<0.0001, vs. initial time, calculated using a paired Student´s t-test after checking the normality distribution by a Shapiro-Wilk test). Right panel: representative images showing the anti-wrinkle effect of a cream containing 2% Uplevity e-Lift peptide solution and after a microcurrent treatment
PERSONAL CARE February 2024
upper facial lifting effect in combination with anti-wrinkle benefits after 28 days and seven days of product treatment, respectively. It has been shown to enhance eyebrow, eyelid, crow´s feet and upper cheek lifting leading to a ‘triorbital’ skin lifting effect. Furthermore, the peptide reduces the
severity of the visibility of wrinkles in the crow´s feet region and underneath the eye. In conclusion, novel peptide is an ideal solution for an overall upper face lifting appearance, inspired by the skin benefits provided by at- home microcurrents devices and showing a similar rejuvenating efficacy.
28 days 2% Uplevity 0 days e-Lift peptide solution Placebo
PC
www.personalcaremagazine.com
Decrease in wrinkle length undneath the eye (%)
Decrease in wrinkle length on the crow's feet (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
